Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
about
Clostridium difficile infection: a review of current and emerging therapiesFidaxomicin: A novel agent for the treatment of Clostridium difficile infectionInfections in Cancer Patients with Solid Tumors: A Review.Clostridium difficile infection: Updates in management.A Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionCost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infectionThe Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.Fecal microbiota transplantation for Clostridium difficile infection: back to the future.Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.The Daniel K. Inouye College of Pharmacy Scripts: Updates on Clostridium difficile Infection: Advances in Laboratory Testing to Aid Diagnosis and Treatment.A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in GermanyNovel therapeutic strategies for Clostridium difficile infections.Management of Clostridium difficile Infection.Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection.A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.Tobacco use as a screener for Clostridium difficile infection outcomes.Evidence-Based Approach to Clostridium difficile Infection.The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort.Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand.Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-ray Analysis.Fidaxomicin and OP-1118 inhibit C. difficile toxin A- and B-mediated inflammatory responses via inhibition of NF-κB activity.Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation.Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lymphoma.
P2860
Q26750157-B5C6064F-8D4F-491B-AE54-2FE2BCBC77A9Q26770175-5241391F-357C-453B-AD87-2761B5432078Q30238576-37C7CC97-6194-4B8E-91B3-66A70347129AQ30239988-68193CDC-E50F-4EF3-99D1-06252C8EE88FQ30240264-0FF5D6EA-1E9E-4199-90F2-A17311195DC8Q34331045-3E7E11B0-0A5F-45F6-A4E2-18FAFB890B7AQ34553267-49404658-FF20-426E-89DB-152509B00208Q35660581-3D7F6A0D-8BA9-41FC-9673-9A4B9E2730CEQ36018079-8767C296-B40A-46A7-9025-7E0F7B93CA85Q36283755-90D1D030-90BF-46A6-963F-950DE8C5189CQ37297999-9B46B26F-C9D0-4D25-AD80-621FBE83EF88Q38632664-87246DE9-FA27-4324-B399-4631037E2D9CQ38787320-5B62EFD0-E52B-44CE-9FDE-3E8B9DA3BC5BQ38904050-3A06827D-9A6D-4A9C-9B2E-D0F7D201BC25Q39361767-EA340ADC-A7CC-4015-8279-13A83A1F48FFQ40065343-7A20A8F2-3EBB-4AD5-B254-37FA42916C94Q40156021-79CFA764-F94E-4B5E-B851-E4A7A07436A4Q40197781-08E1CD5C-D091-495B-9131-7CEB81BE161FQ40513250-3981FB99-D635-4832-AB91-E26A9745C8CEQ40721471-9B5F938A-DFE5-42CC-9243-72FD4D29FADFQ41860568-6CD1B371-D5D3-4B9E-97C1-9FD268171DACQ46412261-1CFEC74C-8D5A-4226-B533-694EB2105B15Q49195473-4AAFCA40-3EC6-47C2-B70F-23CD1D20E12CQ49201152-EC2EDBA7-D061-49D5-8540-4011B5762B8BQ50088077-070768B0-C017-43DA-831B-977AE9D01BA2Q51029174-14904165-6AC4-4778-A8C5-F2CCC2FBB4DA
P2860
Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Clinical efficacy of fidaxomic ...... indirect treatment comparison.
@en
type
label
Clinical efficacy of fidaxomic ...... indirect treatment comparison.
@en
prefLabel
Clinical efficacy of fidaxomic ...... indirect treatment comparison.
@en
P2093
P2860
P356
P1476
Clinical efficacy of fidaxomic ...... indirect treatment comparison.
@en
P2093
Cristina Ivanescu
Dilip Nathwani
Isaac A O Odeyemi
Olatunji Odufowora-Sita
Peny Retsa
P2860
P304
P356
10.1093/JAC/DKU261
P407
P577
2014-07-28T00:00:00Z